RE:RE:RE:Pfizer & BioNTech partnershipI'm sure this has been posted before!
Many companies that list on TSXV eventually grow to meet the listing requirements of TSX and choose to graduate to the senior board. Hundreds of companies have followed this path. In fact, one in five companies in the S&P/TSX Composite Index are graduates of TSXV.
Once your company is ready, we can help your company graduate to TSX in an efficient and economical manner. Consider these benefits of graduation:
Cost savings
- TSX listing application fee (CDN$10,000) will be waived for eligible TSXV issuers. Original Listing Fees will still apply.
Reduction of documentation
- Certain issuer information on file with TSXV can be accessed by TSX, reducing the number of documents required to be submitted.
Waiver of sponsorship
- Sponsorship requirements may be waived for qualified TSXV issuers.*
Once listed on TSX, additional benefits may include:
- Increased access to capital
- Enhanced reputation from meeting the minimum standards of a senior exchange board
- Greater visibility – TSXV graduates listed on TSX are covered by an average of five analysts
- Access to institutional capital – institutional investors have invested $15 Billion in TSXV graduates
- Enhanced liquidity on world markets – roughly 40% of TSX trading is originated by international headquartered Investment Dealers
- Escrow policies may be reduced upon graduation to TSX
- Improved M&A opportunities
- A TSX listing is a requirement for inclusion in the majority of indices and composites
*Some conditions apply. See Part III and Appendix A of the Toronto Stock Exchange Company Manual for complete details.
Please see our Graduation Information Sheet for more information.
For more information on the graduation process, contact Business Development.
CancerSlayer wrote
Infinity wrote: Agree, a joint venture is the best case scenario. There is no way that Biontech could have acheived worldwide marketing of their vaccine without Pfizer, not a chance..
However, to establish a really good joint venture, you need to have
1. Excellent Clinical Test results. Peer reviews of other Urological Oncologists who specialise in Blader cancer treatment.
2. The share price has to move closer to the $ 5.00 mark to establish a joint venture that is favourable to the Share holders.
3. To achieve this goal, we need to have TLT listed in TSX, Nasdaq, or NYSE. To be listed in the larger exchanges the share price and market cap has to move up....
4. Everything hinges on the Clinical Test results and obtaining Break through Designation,,,
I truly believe, we are close to achieving this Goal and RDW is biding his time so that we can all get a joint venture under favourable terms.
When it comes to time frame, my guess is that we are still 1 to 2 years away from a joint venture. We will very likely have good results from the Vaccine side and that should ease the cash flow requirments to last the 2 years time frame.
In the mean time, if we have someone really talented leading the device marketing team for the Laser, we should be able to achieve the goals sooner....TLT may even spin off the Laser division completely to concentrate on the Anti cancer and the Vaccine research..
Any which way you look at it, TLT is poised to grow and take off within the next two years time...IMO
Agree....a JV would be ideal, & not until we are FDA approved for this indication, on a real exchange & preferably sitting at least in the $5-10 range. The real question is, how do we reasonably get there?
A BTD is a significant milestone achievement. Though on this exchange, I expect it would lead to one small step-up in share price, yet one giant leap away from a worthwhile up listing (Nasdaq, etc.) imo. Remaining parked on this exchange until drug approval may be the best option...more shares to accumulate, which works for me.